The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer
EPI Data Slicer